Scholarlink

Background <p>Type 2 diabetes mellitus (T2DM) is a growing global health challenge, necessitating effective therapies that improve glycemic control and promote weight loss. Ecnoglutide, a novel cAMP-biased GLP-1 (glucagon-like peptide-1) receptor agonist, has emerged as a promising therapeutic option.</p> Methods <p>A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA and AMSTAR-2 guidelines. Electronic databases were searched up to February 2026. Eligible studies included adult patients with T2DM comparing ecnoglutide with placebo or active comparators. Outcomes included glycemic parameters, anthropometric measures, metabolic indices, and safety. Data were pooled using a random-effects model, and certainty of evidence was assessed using GRADE.</p> Results <p>Three RCTs comprising 979 participants were included. Ecnoglutide significantly reduced HbA1c (MD -0.57%, 95% CI -0.86 to -0.29) and fasting plasma glucose (MD -1.11 mmol/L, 95% CI -1.58 to -0.65), with a higher proportion achieving target HbA1c (RR 1.57, 95% CI 1.37–1.80). Significant reductions in body weight (MD -1.83&#xa0;kg) and waist circumference (MD -1.53&#xa0;cm) were also observed. Improvements in insulin resistance and lipid parameters were noted. Exploratory subgroup analyses did not establish a clear dose response relationship, while short-term trials showed larger glycemic reductions compared with longer follow up. Adverse events were more frequent but not statistically significant, with no increase in serious adverse events.</p> Conclusion <p>Ecnoglutide demonstrates significant efficacy in improving glycemic control and weight-related outcomes in T2DM, with a safety profile comparable to existing GLP-1 receptor agonists. However, larger and longer-term studies are needed to confirm its cardiovascular benefits and long-term safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Saaed Abunada,
  • Omar Abunada,
  • Fnu Vivek,
  • Lakhveer Rathi,
  • Fnu Muskan,
  • Jiyanth Parkash,
  • Saqlain Nazeer,
  • Fnu Anchal,
  • Fnu Danial,
  • Kashish Turesh,
  • Amjad Ali,
  • Faizan Qureshi,
  • Mahir Tesfaye

摘要

Background

Type 2 diabetes mellitus (T2DM) is a growing global health challenge, necessitating effective therapies that improve glycemic control and promote weight loss. Ecnoglutide, a novel cAMP-biased GLP-1 (glucagon-like peptide-1) receptor agonist, has emerged as a promising therapeutic option.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted following PRISMA and AMSTAR-2 guidelines. Electronic databases were searched up to February 2026. Eligible studies included adult patients with T2DM comparing ecnoglutide with placebo or active comparators. Outcomes included glycemic parameters, anthropometric measures, metabolic indices, and safety. Data were pooled using a random-effects model, and certainty of evidence was assessed using GRADE.

Results

Three RCTs comprising 979 participants were included. Ecnoglutide significantly reduced HbA1c (MD -0.57%, 95% CI -0.86 to -0.29) and fasting plasma glucose (MD -1.11 mmol/L, 95% CI -1.58 to -0.65), with a higher proportion achieving target HbA1c (RR 1.57, 95% CI 1.37–1.80). Significant reductions in body weight (MD -1.83 kg) and waist circumference (MD -1.53 cm) were also observed. Improvements in insulin resistance and lipid parameters were noted. Exploratory subgroup analyses did not establish a clear dose response relationship, while short-term trials showed larger glycemic reductions compared with longer follow up. Adverse events were more frequent but not statistically significant, with no increase in serious adverse events.

Conclusion

Ecnoglutide demonstrates significant efficacy in improving glycemic control and weight-related outcomes in T2DM, with a safety profile comparable to existing GLP-1 receptor agonists. However, larger and longer-term studies are needed to confirm its cardiovascular benefits and long-term safety.